Fighting tuberculosis: An old disease with new challenges

Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide into 21st century. The mortality and spread of this disease has further been aggravated because of synergy of this disease with HIV. A number of anti‐TB drugs are ineffective against this disease be...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal research reviews 2005-01, Vol.25 (1), p.93-131
Main Authors: Tripathi, Rama P., Tewari, Neetu, Dwivedi, Namrata, Tiwari, Vinod K.
Format: Article
Language:English
Subjects:
anti-tuberculosis drugs
Antitubercular Agents - chemistry
Antitubercular Agents - therapeutic use
arabinogalactan
arabinosyl transferase
Drug Design
galactopyranosyl mutase
Human immunodeficiency virus
Humans
isocitrate lyase
latent tuberculosis
MDR TB
Mycobacterium tuberculosis
mycolic acid biosynthesis
mycolyl transferase
peptidoglycan
Social Class
tuberculosis
Tuberculosis - drug therapy
Tuberculosis - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide into 21st century. The mortality and spread of this disease has further been aggravated because of synergy of this disease with HIV. A number of anti‐TB drugs are ineffective against this disease because of development of resistance strains. Internationally efforts are being made to develop new anti‐tubercular agents. A number of drug targets from cell wall biosynthesis, nucleic acid biosynthesis, and many other biosynthetic pathways are being unraveled throughout the world and are being utilized for drug development. In this review, socioeconomic problems in developing countries, efforts to control this disease in different individuals, the targets (known already and newly discovered), existing anti‐tubercular agents including natural products and lead molecules, and the future prospects to develop new anti‐TB agents are described. © 2004 Wiley Periodicals, Inc.
ISSN:0198-6325
1098-1128
DOI:10.1002/med.20017